What are the side effects of ziftomenib-Komzifti?

Ziftomenib-Komzifti is a new drug used to treat relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In clinical application, although ziftomenib provides patients with a new treatment option, it is also accompanied by a series of side effects.

According to clinical trial data, the incidence of common adverse reactions of ziftomenib is over 20%, mainly including the following: infection by unknown pathogens, bleeding, diarrhea, nausea, fatigue, edema, bacterial infection, musculoskeletal pain, differentiation syndrome, pruritus, fever, neutropenia, and elevated transaminases. The occurrence of these side effects may affect the patient's daily life and overall health, so patients need to closely monitor their body's response when using this drug.

In addition, ziftomenib may also cause some laboratory abnormalities, with an incidence rate of more than 10%, mainly including increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT), decreases in potassium, albumin and sodium, and increases in creatinine, alkaline phosphatase and bilirubin. These laboratory abnormalities require regular monitoring so that treatment options can be adjusted promptly to avoid serious complications.

During the use of ziftomenib, medical staff should fully inform patients of possible side effects and instruct patients on how to identify and respond to these adverse reactions. If the patient develops the above discomfort symptoms while taking the medicine, he should report it to the doctor in time for necessary evaluation and treatment. In addition, regular laboratory examinations are also important measures to ensure patient safety and drug efficacy.

In short, as a new treatment drug, zitumenib brings hope to patients with relapsed or refractoryNPM1-mutated acute myeloid leukemia, but it is also necessary to be wary of its potential side effects. Through reasonable monitoring and management, patients can be helped to better cope with challenges during treatment and improve the safety and effectiveness of treatment.

Reference materials:https://www.drugs.com/komzifti.html